10-Q: Air Industries Group Reports Q1 2025 Results: Sales Dip, Net Loss Widens Amidst Operational Challenges

Air Industries Group's Q1 2025 results reveal a decrease in net sales and an increased net loss compared to Q1 2024, alongside ongoing efforts to address financial and operational challenges.

Summary

• Air Industries Group reported net sales of $12.135 million for the three months ended March 31, 2025, a decrease of 13.7% compared to $14.061 million in the same period of 2024.
• The company's net loss widened to $988,000 for Q1 2025, compared to a net loss of $706,000 for Q1 2024.
• Gross profit increased slightly to $2.034 million from $1.906 million, with the gross profit percentage rising to 16.8% from 13.6%.
• Operating expenses increased by $615,000 to $2.780 million, driven by higher stock-based compensation and professional fees.
• The company's backlog as of March 31, 2025, was $120.6 million, with total unfilled contract values amounting to $270.3 million.
• Air Industries Group is working to refinance its debt and is in discussions with its lender and holders of related party notes.
• The company's Current Credit Facility expires on December 30, 2025, raising concerns about its ability to continue as a going concern.
• The company met the Fixed Charge Coverage Ratio covenant of 1.05x for the twelve-month rolling period ending March 31, 2025.
• The company's cash balance decreased to $285,000 from $753,000 at the end of 2024.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company shows some improvement in gross profit margin and meets its Fixed Charge Coverage Ratio, the decrease in net sales, increased net loss, and going concern issues weigh heavily on the overall outlook.

Positives

• Gross profit margin improved to 16.8% in Q1 2025 from 13.6% in Q1 2024, indicating improved operational efficiency.
• The company met its Fixed Charge Coverage Ratio covenant of 1.19x, exceeding the required 1.05x, demonstrating its ability to manage its fixed costs.
• The company's backlog as of March 31, 2025, was $120.6 million, with total unfilled contract values amounting to $270.3 million, indicating future revenue potential.
• The company is actively negotiating with its lender and related party noteholders to refinance its debt, which could improve its financial flexibility.

Negatives

• Net sales decreased by 13.7% to $12.135 million in Q1 2025 compared to $14.061 million in Q1 2024, indicating a slowdown in business activity.
• Net loss increased to $988,000 in Q1 2025 from $706,000 in Q1 2024, reflecting increased financial strain.
• Operating expenses rose to $2.780 million due to increased stock-based compensation and professional fees, impacting profitability.
• The Current Credit Facility expires on December 30, 2025, raising going concern issues, which creates uncertainty about the company's future.
• Cash balance decreased to $285,000 from $753,000 at the end of 2024, indicating a weakening liquidity position.

Risks

• The expiration of the Current Credit Facility on December 30, 2025, raises substantial doubt about the company's ability to continue as a going concern.
• Failure to refinance existing debt or obtain additional working capital could have a material adverse effect on the company's business and financial condition.
• The company's reliance on a few large aerospace and defense prime contractors concentrates its revenue stream, making it vulnerable to changes in their demand.
• The company's operations are subject to risks associated with sole-source suppliers, which could disrupt production if these suppliers are unable to provide parts.
• The company's material weakness in internal controls over financial reporting related to IT systems could lead to errors in financial reporting.

Future Outlook

The company anticipates boosting sales during the remainder of 2025, attaining profitability, and improving its financial position, supported by a $120.6 million backlog and potential orders against LTA agreements.

Management Comments

• Management plans are to increase net sales for fiscal 2025 as compared to fiscal 2024.
• The Company believes that these plans are supported by the Company's 18 month funded backlog which, as of March 31, 2025, was $120.6 million.
• Management has begun negotiations with both the lender of its Current Credit Facility and holders of its related party notes.
• During the first quarter of 2025 and looking forward, our business strategy is geared towards achieving sustainable and profitable business growth.
• We are firmly focused on securing new contract awards, improving operations and successful execution.

Industry Context

Air Industries Group operates in the precision components and assemblies sector for large aerospace and defense contractors, facing competition in winning new contract awards, which requires delivering superior quality products quickly and at lower prices.

Comparison to Industry Standards

• It is difficult to compare Air Industries Group's results directly to industry standards without specific competitor data.
• However, companies like TransDigm Group, HEICO Corporation, and Triumph Group are key players in the aerospace component manufacturing sector.
• These companies often have higher profit margins and stronger balance sheets due to their focus on proprietary products and aftermarket services.
• Air Industries Group's reliance on a few large contracts and its debt burden put it at a disadvantage compared to these larger, more diversified competitors.
• The company's ability to secure long-term agreements (LTAs) is a positive sign, but its financial performance needs to improve to align with industry leaders.

Legal Proceedings

• Contract Pharmacal Corp. commenced an action, relating to a Sublease entered into between the Company and Contract Pharmacal in May 2018 with respect to the property formerly occupied by the Company's former subsidiary, Welding Metallurgy, Inc (WMI), at 110 Plant Avenue, Hauppauge, New York.
• Contract Pharmacal sought damages for an amount in excess of $1,000,000 for the Company's failure to make the entire premises available by what it claims was the Sublease commencement date.
• On July 8, 2021, the Court denied Contract Pharmacal's motion for summary judgement.
• On March 10, 2022, Contract Pharmacal filed an appeal to the Courts decision with the Appellate Division.
• On March 28, 2024, Contract Pharmacal filed a motion to reargue the appeal previously denied by the Appellate Division.

Related Party Transactions

• From 2016 through 2020, the Company entered into various subordinated notes payable and convertible subordinated notes payable (together referred to as Related Party Notes) with Michael and Robert Taglich which generated proceeds to the Company totaling $6,550,000.
• In connection with the issuance of the Related Party Notes, Michael and Robert Taglich were issued a total of 35,508 shares of common stock and Taglich Brothers, Inc. was issued promissory notes totaling $554,000 for placement agency fees.
• For the three month period ended March 31, 2025, the Company paid a total of $1,291,000 of principal payments.
• Of the $1,291,000 paid, $1,050,000 was paid to Michael Taglich and $241,000 was paid to Taglich Brothers, Inc.

Stakeholder Impact

• Shareholders face uncertainty due to the company's going concern issues and potential need for refinancing.
• Employees may be concerned about job security given the company's financial challenges.
• Customers may be affected by potential disruptions in supply if the company faces financial difficulties.
• Suppliers may face increased credit risk due to the company's weakened financial position.
• Creditors face increased risk of default due to the company's debt burden and going concern issues.

Next Steps

• The company intends to continue to dispute the validity of the claim asserted by Contract Pharmacal.
• The company expects to additionally invest approximately $750,000 during the remainder of 2025 for new or upgraded equipment.
• The company is continuing to test controls and procedures designed to remediate the aforementioned material weakness.
• The company will continue discussions with its lender under the Current Credit Facility and the holders of the Related Party Notes to explore potential extensions or refinancing of our obligations.

Key Dates

Keywords

financial results, quarterly report, net sales, net loss, backlog, debt, aerospace, defense, Air Industries Group